Aerovate Therapeutics Reports Quarterly Loss but Maintains Financial Stability
Aerovate Therapeutics, a prominent biopharmaceutical company, recently disclosed its financial performance for the quarter ending on November 13, 2023. The ...
Tag: AVTE
Aerovate Therapeutics Q3 Financial Results Fall Short of Expectations
On November 13, 2023, at 08:00 AM, Aerovate Therapeutics unveiled its Q3 financial results, marking an important milestone for the ...
Investment and Financial Performance Analysis of Aerovate Therapeutics: A Look into Golden State Equity Partners’ Stake Acquisition
On September 15, 2023, it was reported that Golden State Equity Partners has acquired a new stake in Aerovate Therapeutics, ...
ProShare Advisors LLC Increases Stake in eBay Inc. as Confidence in Company Grows
On September 15, 2023, it was reported that ProShare Advisors LLC, an investment firm, has increased its stake in eBay ...
Aerovate Therapeutics Receives Increased Investment from Atlas Venture and Faces Investor Scrutiny After Earnings Miss
September 12, 2023 - Atlas Venture Life Science Advisors LLC, a prominent institutional investor, has increased its stake in Aerovate ...
Investment Management Firm Reduces Stake in Waters Co., Impacting Investment Portfolio
On September 12, 2023, it was reported that investment management firm Beck Mack & Oliver LLC has reduced its stake ...
Aerovate Therapeutics Faces Earnings Disappointment, Raises Concerns for Investors
On August 20, 2023, Aerovate Therapeutics (NASDAQ: AVTE) released its latest earnings report. The company's financial results for the quarter ...
Aerovate Therapeutics shares open strong amid industry interest and insider trading activity.
Aerovate Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing treatments for cardiopulmonary diseases, saw its shares open up at $19.30 ...